Polomar Health Services, Inc.
PMHS
Other OTC0.12
USD
- -
- -
CIK
0001265521
ISIN
US8983912069
CUSIP
898391206
Return %
Stock
S&P500
1Y
-72.01
18.99
3Y
-90.56
64.75
5Y
-99.98
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Terrence Tierney
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 10940 Wilshire Boulevard Los Angeles CA United States of America 90024
- IPO Date
- Feb 9, 2009
- CIK
- 0001265521
- Website
- polomarhs.com
- Similar Companies
- Business
- Polomar Health Services, Inc. engages in retail compounding pharmacy services and online platforms for prescription fulfillment and weight-management medications, with operations anchored in the United States. Founded in the early 2020s, the company maintains its headquarters in [headquarters location not publicly disclosed in available sources], and seeks to expand through online platforms and third-party telehealth partnerships to broaden access to pharmaceutical products and services. Main products and services - Retail compounding pharmacy services: customized prescription compounding for individual patients, including sterile and non-sterile formulations. - Online platforms for prescription fulfillment: digital interfaces that connect patients with licensed providers and pharmacies to process and dispense medications prescribed via telehealth channels. - Weight management medications platform: SlimRx, an online prescribing and fulfillment channel for weight loss medications, including semaglutide-based therapies, with physician-assisted prescription pathways. - Upcoming and planned product lines: PoloMeds, a planned extension to fulfill prescriptions for diabetes medications, erectile dysfunction therapies, and exclusive dermatological formulations; dermatology-focused compounding and product offerings. Latest major changes - Strategic partnerships and alliances: expands prescription fulfillment through third-party telehealth platforms; ongoing collaborations to broaden geographic reach and regulatory clearance for cross-state operations. - Product launches and expansions: SlimRx operates as the existing online platform for weight loss medications; PoloMeds is planned for launch in 2025 to broaden product and therapy categories, including diabetes and dermatology medications. - Corporate and regulatory changes: pursuing state-by-state expansion of pharmacy operations; seeking regulatory approvals and export permits to enable international or cross-border pharmacy activities; adjustments to corporate staffing to support regulatory, legal, and compliance functions. Industry context and geography - Industry: retail pharmacy services with a focus on telehealth-enabled prescription fulfillment and online medication platforms. - Segments: retail compounding, telehealth fulfillment services, weight-management pharmacotherapy platforms, specialty dermatology and diabetes medication offerings. - Markets: United States, with plans for expansion to additional states and potential export pathways; headquarters and primary operations located in the United States, with public disclosures indicating a regulatory and licensing emphasis for growth. - Corporate relationships: operates as an independent company focused on pharmacy services, with potential collaborations and licensing agreements to access proprietary formulations and delivery capabilities. Founding and leadership context - Founding year: early 2020s (specific year not consistently disclosed in public summaries). - Headquarters: United States-based (exact city not consistently disclosed in public disclosures). Subsidiaries and brands - SlimRx: online platform connecting patients with licensed physicians to obtain weight loss medications. - PoloMeds: planned platform to fulfill a broader range of prescription therapies, including diabetes, erectile dysfunction medications, and exclusive dermatology formulations. Notes - The company reports a focus on expanding its wholesale and telehealth fulfillment capabilities, leveraging strategic partnerships and new product launches to accelerate growth, while navigating regulatory requirements across states. Citations - Polomar Health Services, Inc. operates retail compounding pharmacy services and third-party telehealth prescription fulfillment platforms, including SlimRx, with plans for PoloMeds expansion; multiple sources reference its online platform strategy and weight-management medication focus. - Public disclosures indicate ongoing strategic partnerships with third-party telehealth platforms and plans to expand pharmacy operations state-by-state, plus regulatory and licensing initiatives to support growth. - Market data and company profiles summarize SlimRx as an online platform for weight loss medications and note PoloMeds as a forthcoming product line with expanded therapy offerings.
Fastbase Inc. Ventures into Artificial Intelligence to Elevate Its Data-Driven Marketing Solutions
Trustfeed Corp (OTC:TRFE) Confirms effectiveness of its Form 10 filing